These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7107397)

  • 1. Chemosensitization of mouse tumors by misonidazole.
    Randhawa VS; Stewart FA; Denekamp J
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):671-4. PubMed ID: 7107397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts.
    Clutterbuck RD; Millar JL; McElwain TJ
    Am J Clin Oncol; 1982 Feb; 5(1):73-8. PubMed ID: 7081141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU.
    Twentyman P; Workman P
    Br J Cancer; 1982 Mar; 45(3):447-55. PubMed ID: 7073938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of cytotoxic drugs by misonidazole (MISO) in Lewis lung tumors of different sizes, and mouse bone marrow.
    Spooner D; Peacock JH; Stephens TC
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):643-6. PubMed ID: 7107390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the mechanism of chemosensitization by misonidazole in vitro.
    Taylor YC; Bump EA; Brown JM
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):705-8. PubMed ID: 7107402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the action of alkylating agents by single high, or chronic low doses of misonidazole.
    McNally NJ; Hinchliffe M; de Ronde J
    Br J Cancer; 1983 Aug; 48(2):271-8. PubMed ID: 6882665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic potential of misonidazole enhancement of alkylating agent cytotoxicity.
    Hirst DG; Brown JM
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):639-42. PubMed ID: 7107389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.
    Hinchliffe M; McNally NJ; Stratford MR
    Br J Cancer; 1983 Sep; 48(3):375-83. PubMed ID: 6615699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced cytotoxicity of antineoplastic agents following prolonged exposure to misonidazole.
    Roizin-Towle LA; Hall EJ
    Br J Cancer; 1981 Aug; 44(2):201-7. PubMed ID: 6168277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole.
    Twentyman PR; Workman P
    Br J Cancer; 1983 Feb; 47(2):187-94. PubMed ID: 6824566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced cytotoxicity of melphalan by prolonged exposure to nitroimidazoles: the role of endogenous thiols.
    Roizin-Towle L; Hall EJ; Flynn M; Biaglow JE; Varnes ME
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):757-60. PubMed ID: 7107410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles.
    Brown JM
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):675-82. PubMed ID: 7050043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of cyclophosphamide cytotoxicity in vivo: a study with misonidazole and fifteen other 1-substituted 2-nitroimidazoles.
    Chaplin DJ; Sheldon PW; Ahmed I; Adams GE
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1647-51. PubMed ID: 6480452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents.
    Brown JM; Hirst DG
    Br J Cancer; 1982 May; 45(5):700-8. PubMed ID: 7082556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced cell killing in lewis lung carcinoma and a human pancreatic-carcinoma xenograft by the combination of cytotoxic drugs and misonidazole.
    Stephens TC; Courtenay VD; Mills J; Peacock JH; Rose CM; Spooner D
    Br J Cancer; 1981 Apr; 43(4):451-7. PubMed ID: 7236488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the ability of some radiosensitizers undergoing clinical trials to act as chemosensitizers.
    Hinchliffe M; McNally NJ
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1635-40. PubMed ID: 6237081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.
    Milas L; Ito H; Hunter N
    Cancer Res; 1983 Jul; 43(7):3050-6. PubMed ID: 6303574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing effect of pre-treatment of cells with misonidazole in hypoxia on their response to melphalan in air.
    Smith E; Stratford IJ; Adams GE
    Br J Cancer; 1982 Jul; 46(1):117-26. PubMed ID: 7104191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of misonidazole radiosensitization by buthionine sulphoximine.
    Rojas A; Smith KA; Soranson JA; Minchinton AI; Middleton RW; Denekamp J
    Radiother Oncol; 1984 Dec; 2(4):325-32. PubMed ID: 6522642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing of hypoxic cell radiosensitizers in vivo.
    Denekamp J
    Cancer Clin Trials; 1980; 3(2):139-48. PubMed ID: 7428137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.